Natriuretic Peptides

Hypertension

Volumn , Issue , 2005, Pages 169-192

  Campese, Vito M ^a   Nadim, Mitra K ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882826870     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50108-3     Document Type: Chapter

References (399)

1. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981, 28:89-94.
2. Yandle TG Biochemistry of natriuretic peptides. J Intern Med 1994, 235:561-576.
3. Mathisen P, Hall C, Simonsen S Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993, 53:41-49.
4. Espiner EA, Richards AM, Yandle TG, et al. Natriuretic hormones. Endocrinol Metab Clin North Am 1995, 24:481-509.
5. Sudoh T, Maekawa K, Kojima M, et al. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989, 159:1427-1434.
6. Yandle TG, Richards AM, Gilbert A, et al. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993, 76:832-838.
7. Sudoh T, Minamino N, Kangawa K, et al. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990, 168:863-870.
8. Tawaragi Y, Fuchimura K, Tanaka S, et al. Gene and precursor structures of human C-type natriuretic peptide. Biochem Biophys Res Commun 1991, 175:645-651.
9. Ogawa Y, Nakao K, Nakagawa O, et al. Human C-type natriuretic peptide. Characterization of the gene and peptide. Hypertension 1992, 19:809-813.
10. Tawaragi Y, Fuchimura K, Nakazato H, et al. Gene and precursor structure of porcine C-type natriuretic peptide. Biochem Biophys Res Commun 1990, 172:627-632.
11. Schweitz H, Vigne P, Moinier D, et al. A new member of the natriuretic peptide family is present in the venom of the Green Mamba (Dendroaspis angusticeps). J Biol Chem 1992, 267:13928-13932.
12. Schulz-Knappe P, Forssmann K, Herbst F, et al. Isolation and structural analysis of "urodilatin," a new peptide of the car-diodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988, 66:752-759.
13. Forssmann WG, Richter R, Meyer M The endocrine heart and natriuretic peptides: Histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol 1998, 110:335-357.
14. Ruskoaho H Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev 1992, 44:479-602.
15. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
16. Itoh H, Nakao K, Saito Y, et al. Radioimmunoassay for brain natriuretic peptide (BNP) detection of BNP in canine brain. Biochem Biophys Res Commun 1989, 158:120-128.
17. Hasegawa K, Fujiwara H, Itoh H, et al. Light and electron microscopic localization of brain natriuretic peptide in relation to atrial natriuretic peptide in porcine atrium. Immunohistocytochemical study using specific monoclonal antibodies. Circulation 1991, 84:1203-1209.
18. Iida T, Hirata Y, Takemura N, et al. Brain natriuretic peptide is cosecreted with atrial natriuretic peptide from porcine cardio-cytes. FEBS Lett 1990, 260:98-100.
19. Komatsu Y, Nakao K, Suga S, et al. C-type natriuretic peptide (CNP) in rats and humans. Endocrinology 1991, 129:1104-1106.
20. Suzuki R, Togashi K, Ando K, et al. Distribution and molecular forms of C-type natriuretic peptide in plasma and tissue of a dogfish, Triakis scyllia. Gen Comp Endocrinol 1994, 96:378-384.
21. Kaneko T, Shirakami G, Nakao K, et al. C-type natriuretic peptide (CNP) is the major natriuretic peptide in human cerebrospinal fluid. Brain Res 1993, 612:104-109.
22. Chen HH, Burnett JC C-type natriuretic peptide: The endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998, 32:S22-S28.
23. Mattingly MT, Brandt RR, Heublein DM, et al. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 1994, 46:744-747.
24. Stingo AJ, Clavell AL, Heublein DM, et al. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992, 263:H1318-H1321.
25. Vollmar AM, Wolf R, Schulz R Co-expression of the natriuretic peptides (ANP, BNP, CNP) and their receptors in normal and acutely involuted rat thymus. J Neuroimmunol 1995, 57:117-127.
26. Stepan H, Faber R, Stegemann S, et al. Expression of C-type natriuretic peptide in human placenta and myometrium in normal pregnancies and pregnancies complicated by intrauterine growth retardation. Preliminary results. Fetal Diagn Ther 2002, 17:37-41.
27. Middendorff R, Muller D, Paust HJ, et al. Natriuretic peptides in the human testis: Evidence for a potential role of C-type natriuretic peptide in Leydig cells. J Clin Endocrinol Metab 1996, 81:4324-4328.
28. Vollmar AM, Gerbes AL, Nemer M, et al. Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology 1993, 132:1872-1874.
29. Heublein DM, Clavell AL, Stingo AJ, et al. C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells. Peptides 1992, 13:1017-1019.
30. Totsune K, Takahashi K, Murakami O, et al. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci (Lond) 1994, 87:319-322.
31. Cataliotti A, Giordano M, De Pascale E, et al. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol Renal Physiol 2002, 283:F464-F472.
32. Schirger JA, Heublein DM, Chen HH, et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999, 74:126-130.
33. Lisy O, Jougasaki M, Heublein DM, et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 1999, 56:502-508.
34. Feller SM, Gagelmann M, Forssmann WG Urodilatin: A newly described member of the ANP family. Trends Pharmacol Sci 1989, 10:93-94.
35. Greenwald JE, Needleman P, Wilkins MR, et al. Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. Am J Physiol 1991, 260:F602-F607.
36. Lowe DG, Klisak I, Sparkes RS, et al. Chromosomal distribution of three members of the human natriuretic peptide receptor/guanylyl cyclase gene family. Genomics 1990, 8:304-312.
37. Maack T, Okolicany J, Koh GY, et al. Functional properties of atrial natriuretic factor receptors. Semin Nephrol 1993, 13:50-60.
38. Koller KJ, Goeddel DV Molecular biology of the natriuretic peptides and their receptors. Circulation 1992, 86:1081-1088.
39. Lincoln TM, Cornwell TL Intracellular cyclic GMP receptor proteins. FASEB J 1993, 7:328-338.
40. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992, 130:229-339.
41. Koller KJ, Lowe DG, Bennett GL, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991, 252:120-123.
42. Nussenzveig DR, Lewicki JA, Maack T Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem 1990, 265:20952-20958.
43. Fuller F, Porter JG, Arfsten AE, et al. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem 1988, 263:9395-9401.
44. Hirata M, Chang CH, Murad F Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. Biochim Biophys Acta 1989, 1010:346-351.
45. Anand-Srivastava MB, Sairam MR, Cantin M Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem 1990, 265:8566-8572.
46. Drewett JG, Ziegler RJ, Trachte GJ Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase. J Pharmacol Exp Ther 1992, 260:689-696.
47. Levin ER Natriuretic peptide C-receptor: More than a clearance receptor. Am J Physiol 1993, 264:E483-E489.
48. Itoh H, Sagawa N, Hasegawa M, et al. Expression of biologically active receptors for natriuretic peptides in the human uterus during pregnancy. Biochem Biophys Res Commun 1994, 203:602-607.
49. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens 1992, 10:1111-1114.
50. Martin ER, Lewicki J, Scarborough RM, et al. Expression and regulation of ANP receptor subtypes in rat renal glomeruli and papillae. Am J Physiol Renal Fluid Electrolyte Physiol 1989, 257:F649-F657.
51. Lohe A, Yeh I, Hyver T, et al. Natriuretic peptide B receptor and C-type natriuretic peptide in the rat kidney. J Am Soc Nephrol 1995, 6:1552-1558.
52. Ikeda T, Itoh H, Komatsu Y, et al. Natriuretic peptide receptors in human artery and vein and rabbit vein graft. Hypertension 1996, 27:833-8337.
53. Nagase M, Ando K, Katafuchi T, et al. Role of natriuretic peptide receptor type C in Dahl salt-sensitive hypertensive rats. Hypertension 1997, 30:177-183.
54. Lin X, Hanze J, Heese F, et al. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 1995, 77:750-758.
55. Fraenkel MB, Aldred GP, McDougall JG Sodium status affects GC-B natriuretic peptide receptor mRNA levels, but not GC-A or C receptor mRNA levels, in the sheep kidney. Clin Sci (Lond) 1994, 86:517-522.
56. Katafuchi T, Mizuno T, Hagiwara H, et al. Modulation by NaCl of atrial natriuretic peptide receptor levels and cyclic GMP responsiveness to atrial natriuretic peptide of cultured vascular endothelial cells. J Biol Chem 1992, 267:7624-7629.
57. Sun JZ, Chen SJ, Majid-Hasan E, et al. Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP. Am J Physiol Renal Physiol 2002, 282:F220-F227.
58. Hystad ME, Oie E, Grogaard HK, et al. Gene expression of natriuretic peptides and their receptors type-A and -C after myocardial infarction in rats. Scand J Clin Lab Invest 2001, 61:139-150.
59. Cohen D, Koh GY, Nikonova LN, et al. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 1996, 271:9863-9869.
60. Lewicki J, Protter A Molecular determinants of natriuretic peptide clearance receptor function. Contemporary Endocrinology: Natriuretic Peptides in Health and Disease 1997, 51-70. Humana Press, Totowa, NJ. W.K. Samson, E.R. Levin (Eds.).
61. Sun JZ, Oparil S, Lucchesi P, et al. Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2001, 281:L155-L163.
62. Sun JZ, Chen SJ, Li G, et al. Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice. Am J Physiol Lung Cell Mol Physiol 2000, 279:L511-L519.
63. Li H, Oparil S, Meng QC, et al. Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia. Am J Physiol 1995, 268:L328-L335.
64. Itoh H, Zheng J, Bird IM, et al. Basic FGF decreases clearance receptor of natriuretic peptides in fetoplacental artery endothelium. Am J Physiol 1999, 277:R541-R547.
65. Paul RV, Wackym PS, Budisavljevic M, et al. Regulation of atrial natriuretic peptide clearance receptors in mesangial cells by growth factors. J Biol Chem 1993, 268:18205-18212.
66. Weston MW, Cintron GB, Giordano AT, et al. Normalization of circulating atrial natriuretic peptides in cardiac transplant recipients. Am Heart J 1994, 127:129-142.
67. Schiebinger RJ, Gomez-Sanchez CE Endothelin: A potent stimulus of atrial natriuretic peptide secretion by superfused rat atria and its dependency on calcium. Endocrinology 1990, 127:119-125.
68. Leskinen H, Vuolteenaho O, Ruskoaho H Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release. Circ Res 1997, 126:587-595.
69. Schiebinger RJ, Baker MZ, Linden J Effect of adrenergic and muscarinic cholinergic agonists on atrial natriuretic peptide secretion by isolated rat atria. Potential role of the autonomic nervous system in modulating atrial natriuretic peptide secretion. J Clin Invest 1987, 80:1687-1691.
70. Focaccio A, Volpe M, Ambrosio G, et al. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 1993, 87:192-198.
71. Gardner DG, Schultz HD Prostaglandins regulate the synthesis and secretion of the atrial natriuretic peptide. J Clin Invest 1990, 86:52-59.
72. Bloch KD, Zamir N, Lichtstein D, et al. Ouabain induces secretion of proatrial natriuretic factor by rat atrial cardiocytes. Am J Physiol 1988, 255:E383-E387.
73. Kaufman S, Deng Y Adrenomedullin suppresses atrial natriuretic factor (ANF) secretion from isolated atrium. Life Sci 1998, 63:1017-1022.
74. Leite MF, Page E, Ambler SK Regulation of ANP secretion by endothelin-1 in cultured atrial myocytes: Desensitization and receptor subtype. Am J Physiol 1994, 267:H2193-H2203.
75. Suzuki E, Hirata Y, Kohmoto O, et al. Cellular mechanisms for synthesis and secretion of atrial natriuretic peptide and brain natriuretic peptide in cultured rat atrial cells. Circ Res 1992, 71:1039-1048.
76. Favaretto AL, Ballejo GO, Albuquerque-Araujo WI, et al. Oxytocin releases atrial natriuretic peptide from rat atria in vitro that exerts negative inotropic and chronotropic action. Peptides 1997, 18:1377-1381.
77. Gutkowska J, Jankowski M, Lambert C, et al. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci USA 1997, 94:11704-11709.
78. Bianciotti LG, de Bold AJ Effect of selective ET(A) receptor blockade on natriuretic peptide gene expression in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol 2000, 279:H93-H101.
79. Bianciotti LG, de Bold AJ Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension. Cardiovasc Res 2001, 49:806-816.
80. Ogawa T, Linz W, Stevenson M, et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 1996, 93:2059-2067.
81. Bianciotti LG, de Bold AJ. Natriuretic peptide gene expression in DOCA-salt hypertension after blockade of type B endothelin receptor. Am J Physiol Heart Circ Physiol 282:H1127-34.
82. Mantymaa P, Vuolteenaho O, Marttila M, et al. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 2002, 133:1470-1473.
83. de Bold AJ, Bruneau BG, Kuroski de Bold ML Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996, 31:7-18.
84. Chiu PJ, Tetzloff G, Romano MT, et al. Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol 1991, 260:R208-R216.
85. Perrella MA, Schwab TR, O'Murchu B, et al. Cardiac atrial natriuretic factor during evolution of congestive heart failure. Am J Physiol 1992, 262:H1248-H1255.
86. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991, 87:1402-1412.
87. Richards AM, Crozier IG, Espiner EA, et al. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 1993, 22:231-236.
88. Kohno M, Horio T, Yokokawa K, et al. Pulmonary arterial brain natriuretic peptide concentration and cardiopulmonary hemodynamics during exercise in patients with essential hypertension. Metabolism 1992, 41:1273-1275.
89. Lang CC, Choy AM, Henderson IS, et al. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci (Lond) 1992, 82:127-131.
90. Kinnunen P, Vuolteenaho O, Ruskoaho H Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993, 132:1961-1970.
91. Hama N, Itoh H, Shirakami G, et al. Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. Biochem Biophys Res Commun 1994, 198:1177-1182.
92. Soleihac JM, Lucan E, Beaumont A, et al. A 94-kDa protein identified as neutral endopeptidase 24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol 1992, 41:609-614.
93. Seymour AA, Abboa-Offei BE, Smith PL, et al. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995, 22:63-69.
94. Dussaule JC, Stefanski A, Bea ML, et al. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1993, 264:F45-F52.
95. Saxenhofer H, Raselli A, Weidmann P, et al. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990, 259:F832-F838.
96. Chen HH, Lainchbury JG, Burnett JC Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide den-droaspsis natriuretic peptide. J Am Coll Cardiol 2002, 40:1186-1191.
97. Sybertz EJ, Chiu PJ, Watkins RW, et al. Neutral metalloen-dopeptidase inhibitors as ANF potentiators: Sites and mechanisms of action. Can J Physiol Pharmacol 1991, 69:1628-1635.
98. Seymour AA, Fennell SA, Swerdel JN Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072. Hypertension 1989, 14:87-97.
99. Kishimoto I, Nakao K, Suga S, et al. Downregulation of C-receptor by natriuretic peptides via ANP-B receptor in vascular smooth muscle cells. Am J Physiol 1993, 265:H1373-H1379.
100. Takei Y, Takano M, Itahara Y, et al. Rainbow trout ventricular natriuretic peptide: Isolation, sequencing, and determination of biological activity. Gen Comp Endocrinol 1994, 96:420-426.
101. Takei Y, Fukuzawa A, Itahara Y, et al. A new natriuretic peptide isolated from cardiac atria of trout, Oncorhynchus mykiss. FEBS Lett 1997, 414:377-380.
102. Greenberg RN, Hill M, Crytzer J, et al. Comparison of effects of uroguanylin, guanylin, and Escherichia coli heat-stable enterotoxin STa in mouse intestine and kidney: Evidence that uroguanylin is an intestinal natriuretic hormone. J Investig Med 1997, 45:276-282.
103. Richards AM, Crozier IG Physiological role of atrial natriuretic peptide. Int J Cardiol 1989, 25:141-143.
104. Janssen WM, de Zeeuw D, van der Hem GK, et al. Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension 1989, 13:640-646.
105. Weidmann P, Hasler L, Gnadinger MP, et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986, 77:734-742.
106. Charles CJ, Espiner EA, Richards AM Cardiovascular actions of ANF: Contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol 1993, 264:R533-R538.
107. Camargo MJ, Kleinert HD, Atlas SA, et al. Ca-dependent hemodynamic and natriuretic effects of atrial extract in isolated rat kidney. Am J Physiol 1984, 246:F447-F456.
108. Briggs JP, Steipe B, Schubert G, et al. Micropuncture studies of the renal effects of atrial natriuretic substance. Pflugers Arch 1982, 395:271-276.
109. Weidmann P, Gnadinger MP, Ziswiler HR, et al. Cardiovascular, endocrine and renal effects of atrial natriuretic peptide in essential hypertension. J Hypertens Suppl 1986, 4:S71-S83.
110. Weder AB, Sekkarie MA, Takiyyuddin M, et al. Antihypertensive and hypotensive effects of atrial natriuretic factor in men. Hypertension 1987, 10:582-589.
111. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993, 76:91-96.
112. Seymour AA, Blaine EH, Mazack EK, et al. Renal and systemic effects of synthetic atrial natriuretic factor. Life Sci 1985, 36:33-44.
113. Gunning M, Ballermann BJ, Silva P, et al. Brain natriuretic peptide: Interaction with renal ANP system. Am J Physiol 1990, 258:F467-F472.
114. Inoue T, Nonoguchi H, Tomita K Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 2001, 51:470-480.
115. Shin SJ, Lee YJ, Tan MS, et al. Increased atrial natriuretic peptide mRNA expression in the kidney of diabetic rats. Kidney Int 1997, 51:1100-1105.
116. Shin SJ, Wen JD, Lee YJ, et al. Increased C-type natriuretic peptide mRNA expression in the kidney of diabetic rats. J Endocrinol 1998, 158:35-42.
117. Morishita Y, Sano T, Ando K, et al. Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun 1991, 176:949-957.
118. Stevens TL, Wei CM, Aahrus LL, et al. Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor. Hypertension 1994, 23:613-618.
119. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994, 89:2232-2240.
120. Kishimoto I, Dubois SK, Garbers DL The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: Acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci USA 1996, 93:6215-6219.
121. Veress AT, Chong CK, Field LJ, et al. Blood pressure and fluid-electrolyte balance in ANF-transgenic mice on high- and low-salt diets. Am J Physiol 1995, 269:R186-R192.
122. Koh GY, Klug MG, Field LJ Atrial natriuretic factor and transgenic mice. Hypertension 1993, 22:634-639.
123. Carstens J, Jensen KT, Pedersen EB Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci (Lond) 1997, 92:397-407.
124. Drummer C, Fiedler F, Konig A, et al. Urodilatin, a kidney-derived natriuretic factor, is excreted with a circadian rhythm and is stimulated by saline infusion in man. J Am Soc Nephrol 1991, 1:1109-1113.
125. Villarreal D, Freeman RH, Johnson RA Renal effects of ANF (95-126), a new atrial peptide analogue, in dogs with experimental heart failure. Am J Hypertens 1991, 4:508-515.
126. John SW, Veress AT, Honrath U, et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 1996, 271:R109-R114.
127. Kita T, Kida O, Yokota N, et al. Effects of brain natriuretic pep-tide-45, a circulating form of rat brain natriuretic peptide, in spontaneously hypertensive rats. Eur J Pharmacol 1991, 202:73-79.
128. Stephenson SL, Kenny AJ The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987, 243:183-187.
129. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991, 84:1581-1588.
130. Supaporn T, Wennberg PW, Wei CM, et al. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci (Lond) 1996, 90:357-362.
131. Suga S, Nakao K, Itoh H, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system.". J Clin Invest 1992, 90:1145-1149.
132. Drewett JG, Fendly BM, Garbers DL, et al. Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J Biol Chem 1995, 270:4668-4674.
133. Itoh H, Pratt RE, Dzau VJ Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990, 86:1690-1697.
134. Doi K, Itoh H, Ikeda T, et al. Adenovirus-mediated gene transfer of C-type natriuretic peptide causes G1 growth inhibition of cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1997, 239:889-894.
135. Wei CM, Aarhus LL, Miller VM, et al. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol 1993, 264:H71-H73.
136. Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation 1993, 88:1004-1009.
137. Fixler R, Hasin Y, Eilam Y, et al. Opposing effects of endothe-lin-1 on C-type natriuretic peptide actions in rat cardiomy-ocytes. Eur J Pharmacol 2001, 423:95-98.
138. Wei CM, Kim CH, Khraibi AA, et al. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension 1994, 23:903-907.
139. Clavell AL, Stingo AJ, Wei CM, et al. C-type natriuretic peptide: A selective cardiovascular peptide. Am J Physiol 1993, 264:R290-R295.
140. Hunt PJ, Richards AM, Espiner EA, et al. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994, 78:1428-1435.
141. Igaki T, Itoh H, Suga S, et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int Suppl 1996, 55:S144-S147.
142. Wei CM, Hu S, Miller VM, et al. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun 1994, 205:765-771.
143. Collins E, Bracamonte MP, Burnett JC, et al. Mechanism of relaxations to dendroaspis natriuretic peptide in canine coronary arteries. J Cardiovasc Pharmacol 2000, 35:614-618.
144. Best PJ, Burnett JC, Wilson SH, et al. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002, 55:375-384.
145. Steinhelper ME, Cochrane KL, Field LJ Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990, 16:301-307.
146. John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267:679-681.
147. Lopez MJ, Wong SK, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995, 378:65-68.
148. Lopez MJ, Garbers DL, Kuhn M The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J Biol Chem 1997, 272:23064-23068.
149. Hutchinson HG, Trindade PT, Cunanan DB, et al. Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res 1997, 35:158-167.
150. Itoh H, Pratt RE, Ohno M, et al. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992, 19:758-761.
151. Horio T, Nishikimi T, Yoshihara F, et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000, 35:19-24.
152. Wu CF, Bishopric NH, Pratt RE Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 1997, 272:14860-14866.
153. Suenobu N, Shichiri M, Iwashina M, et al. Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol 1999, 19:140-146.
154. Itoh H, Nakao K Antagonism between the vascular renin-angiotensin and natriuretic peptide systems in vascular remodelling. Blood Press Suppl 1994, 5:49-53.
155. Kohno M, Yasunari K, Yokokawa K, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991, 87:1999-2004.
156. Furuya M, Aisaka K, Miyazaki T, et al. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun 1993, 193:248-253.
157. Morishita R, Gibbons GH, Pratt RE, et al. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest 1994, 94:824-829.
158. Suga S, Itoh H, Komatsu Y, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993, 133:3038-3041.
159. Tsutsui M, Yanagihara N, Minami K, et al. C-type natriuretic peptide stimulates catecholamine synthesis through the accumulation of cyclic GMP in cultured bovine adrenal medullary cells. J Pharmacol Exp Ther 1994, 268:584-589.
160. Morishige K, Shimokawa H, Yamawaki T, et al. Local aden-ovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J Am Coll Cardiol 2000, 35:1040-1047.
161. Canaan-Kuhl S, Ostendorf T, Zander K, et al. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int 1998, 53:1143-1151.
162. Schultz HD, Gardner DG, Deschepper CF, et al. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol 1988, 255:R6-R13.
163. Yang RH, Jin HK, Wyss JM, et al. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. Hypertension 1992, 19:198-205.
164. Ermirio R, Avanzino GL, Ruggeri P, et al. Cardiovascular effects of microinjection of ANF and brain natriuretic peptide into ventrolateral medulla. Am J Physiol 1990, 259:R32-R37.
165. Yang RH, Jin HK, Chen YF, et al. Blockade of endogenous anterior hypothalamic atrial natriuretic peptide with monoclonal antibody lowers blood pressure in spontaneously hypertensive rats. J Clin Invest 1990, 86:1985-1990.
166. Oparil S, Chen YF, Peng N, et al. Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Front Neuroendocrinol 1996, 17:212-246.
167. Grove KL, Goncalves J, Picard S, et al. Comparison of ANP binding and sensitivity in brains from hypertensive and nor-motensive rats. Am J Physiol 1997, 272:R1344-R1353.
168. Imura H, Nakao K, Itoh H The natriuretic peptide system in the brain: Implications in the central control of cardiovascular and neuroendocrine functions. Front Neuroendocrinol 1992, 13:217-249.
169. Burrell LM, Lambert HJ, Baylis PH Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans. Am J Physiol 1991, 260:R475-R479.
170. Blackburn RE, Samson WK, Fulton RJ, et al. Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. Am J Physiol 1995, 269:R245-R251.
171. Kubo T, Ando S, Picton P, et al. Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure. J Hypertens 2001, 19:619-626.
172. Back H, Stumpf WE, Ando E, et al. Immunocytochemical evidence for CDD/ANP-like peptides in strands of myoendocrine cells associated with the ventricular conduction system of the rat heart. Anat Embryol (Berl) 1986, 175:223-226.
173. Wharton J, Anderson RH, Springall D, et al. Localisation of atrial natriuretic peptide immunoreactivity in the ventricular myocardium and conduction system of the human fetal and adult heart. Br Heart J 1988, 60:267-274.
174. Hansson M, Eriksson A, Forsgren S Natriuretic peptide immunoreactivity in nerve structures and Purkinje fibres of human, pig and sheep hearts. Histochem J 1997, 29:329-336.
175. Debinski W, Gutkowska J, Kuchel O, et al. ANF-like peptide(s) in the peripheral autonomic nervous system. Biochem Biophys Res Commun 1986, 134:279-284.
176. Atchison DJ, Ackermann U The interaction between atrial natriuretic peptide and cardiac parasympathetic function. J Auton Nerv Syst 1993, 42:81-88.
177. Lang CC, Choy AM, Balfour DJ, et al. Prazosin attenuates the natriuretic response to atrial natriuretic factor in man. Kidney Int 1992, 42:433-441.
178. Toki S, Morishita Y, Sano T, et al. HS-142-1, a novel non-peptide ANP antagonist, blocks the cyclic GMP production elicited by natriuretic peptides in PC12 and NG108-15 cells. Neurosci Lett 1992, 135:117-120.
179. Samson WK, Skala KD, Huang FL CNP-22 stimulates, rather than inhibits, water drinking in the rat: Evidence for a unique biological action of the C-type natriuretic peptides. Brain Res 1991, 568:258-285.
180. Trachte GJ, Drewett JG C-type natriuretic peptide neuromod-ulates independently of guanylyl cyclase activation. Hypertension 1994, 23:38-43.
181. Samson WK, Huang FL, Fulton RJ C-type natriuretic peptide mediates the hypothalamic actions of the natriuretic peptides to inhibit luteinizing hormone secretion. Endocrinology 1993, 132:504-509.
182. Vatta MS, Presas M, Bianciotti LG, et al. B and C types natriuretic peptides modulate norepinephrine uptake and release in the rat hypothalamus. Regul Pept 1996, 65:175-184.
183. Wilcox JN, Augustine A, Goeddel DV, et al. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 1991, 11:3454-3462.
184. Tsukagoshi H, Shimizu Y, Kawata T, et al. Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept 2001, 99:21-29.
185. Kiemer AK, Hartung T, Vollmar AM cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages. J Immunol 2000, 165:175-181.
186. Kiemer AK, Baron A, Gerbes AL, et al. The atrial natriuretic peptide as a regulator of Kupffer cell functions. Shock 2002, 17:365-371.
187. Kiemer AK, Vollmar AM, Bilzer M, et al. Atrial natriuretic peptide reduces expression of TNF-alpha mRNA during reperfusion of the rat liver upon decreased activation of NF-kappaB and AP-1. J Hepatol 2000, 33:236-246.
188. Kiemer AK, Weber NC, Vollmar AM Induction of IkappaB: Atrial natriuretic peptide as a regulator of the NF-kappaB pathway. Biochem Biophys Res Commun 2002, 295:1068-1076.
189. Kiemer AK, Weber NC, Furst R, et al. Inhibition of p38 MAPK activation via induction of MKP-1: Atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 2002, 90:874-881.
190. Collard CD, Agah A, Reenstra W, et al. Endothelial nuclear fac-tor-kappaB translocation and vascular cell adhesion molecule-1 induction by complement: Inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler Thromb Vasc Biol 1999, 19:2623-2629.
191. Burnett JC, Granger JP, Opgenorth TJ Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984, 247:F863-F866.
192. Haloui M, Messika-Zeitoun D, Louedec L, et al. Potentiation of urinary atrial natriuretic peptide interferes with macula densa function. Cardiovasc Res 2001, 51:542-552.
193. McGregor A, Richards M, Espiner E, et al. Brain natriuretic peptide administered to man Actions and metabolism. J Clin Endocrinol Metab 1990, 70:1103-1107.
194. Hunt PJ, Espiner EA, Nicholls MG, et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996, 81:3871-3876.
195. Totsune K, Takahashi K, Murakami O, et al. Natriuretic peptides in the human kidney. Hypertension 1994, 24:758-762.
196. Davidson NC, Barr CS, Struthers AD C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 1996, 93:1155-1159.
197. Walther T, Schuitheiss HP, Tschope C Impaired angiotensin II regulation of renal C-type natriuretic peptide mRNA expression in experimental diabetes mellitus. Cardiovasc Res 2001, 51:562-566.
198. Kotridis P, Kokkas B, Karamouzis M, et al. Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Press 2002, 11:91-94.
199. Heringlake M, Bahlmann L, Klaus S, et al. Effects of angiotensin II and the AT(1) receptor antagonist losartan on the renal excretion of urodilatin. Kidney Blood Press Res 2001, 24:79-83.
200. Maack T Role of atrial natriuretic factor in volume control. Kidney Int 1996, 49:1732-1737.
201. Morita H, Hagiike M, Horiba T, et al. Effects of brain natriuretic peptide and C-type natriuretic peptide infusion on urine flow and jejunal absorption in anesthetized dogs. Jpn J Physiol 1992, 42:349-353.
202. Takagi K, Araki N, Suzuki K Relaxant effect of C-type natriuretic peptide on guinea-pig tracheal smooth muscle. Arzneimittelforschung 1992, 42:1329-1331.
203. Geary CA, Goy MF, Boucher RC Synthesis and vectorial export of cGMP in airway epithelium: Expression of soluble and CNP-specific guanylate cyclases. Am J Physiol 1993, 265:L598-L605.
204. Brusq JM, Mayoux E, Guigui L, et al. Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol 1999, 128:206-212.
205. Nir A, Zhang DF, Fixler R, et al. C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol 2001, 412:195-201.
206. Beaulieu P, Cardinal R, Page P, et al. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol 1997, 273:H1933-H1940.
207. Beaulieu P, Cardinal R, De Lean A, et al. Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs. Br J Pharmacol 1996, 118:1790-1796.
208. Hirose M, Furukawa Y, Kurogouchi F, et al. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J Pharmacol Exp Ther 1998, 286:70-76.
209. Pierkes M, Gambaryan S, Boknik P, et al. Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice. Cardiovasc Res 2002, 53:852-861.
210. Shah AM, Mebazaa A, Wetzel RC, et al. Novel cardiac myofilament desensitizing factor released by endocardial and vascular endothelial cells. Circulation 1994, 89:2492-2497.
211. Suda M, Ogawa Y, Tanaka K, et al. Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc Natl Acad Sci USA 1998, 95:2337-2342.
212. Pfeifer A, Aszodi A, Seidler U, et al. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science 1996, 274:2082-2086.
213. Hunt PJ, Espiner EA, Richards AM, et al. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am J Physiol 1995, 269:R1397-R1403.
214. Hu RM, Levin ER, Pedram A, et al. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J Biol Chem 1992, 267:17384-17389.
215. Ogawa Y, Itoh H, Tamura N, et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 1994, 93:1911-1921.
216. Itoh H, Nakao K, Mukoyama M, et al. Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats. J Clin Invest 1989, 84:145-154.
217. Jin H, Mathews C, Chen YF, et al. Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats. Am J Hypertens 1992, 5:210-218.
218. Jin HK, Chen YF, Yang RH, et al. Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats. Hypertension 1988, 11:739-744.
219. Jin HK, Yang RH, Chen YF, et al. Atrial natriuretic factor prevents NaCl-sensitive hypertension in spontaneously hypertensive rats. Hypertension 1990, 15:170-176.
220. Onwochei MO, Rapp JP Hyposecretion of atrial natriuretic factor by prehypertensive Dahl salt-sensitive rat. Hypertension 1989, 13:440-448.
221. Jin H, Chen YF, Yang RH, et al. Atrial natriuretic factor in NaCl-sensitive and NaCl-resistant spontaneously hypertensive rats. Hypertension 1989, 14:404-412.
222. Jin HK, Yang RH, Chen YF, et al. Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats. Am J Hypertens 1991, 4:449-455.
223. Yokota N, Bruneau BG, Kuroski de Bold ML, et al. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994, 94:1938-1946.
224. Schiffrin EL, St-Louis J, Essiambre R Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. J Hypertens 1988, 6:565-572.
225. Nakaoka H, Kitahara Y, Amano M, et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension 1987, 10:221-225.
226. Talartschik J, Eisenhauer T, Schrader J, et al. Low atrial natriuretic peptide plasma concentrations in 100 patients with essential hypertension. Am J Hypertens 1990, 3:45-47.
227. Montorsi P, Tonolo G, Polonia J, et al. Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension 1987, 10:570-576.
228. Dessi-Fulgheri P, Palermo R, Di Noto G, et al. Plasma levels of atrial natriuretic factor in mild to moderate hypertensives without signs of left ventricular hypertrophy: Correlation with the known duration of hypertension. J Hum Hypertens 1988, 2:177-182.
229. Kohno M, Yasunari K, Matsuura T, et al. Circulating atrial natriuretic polypeptide in essential hypertension. Am Heart J 1987, 113:1160-1163.
230. Sagnella GA, Markandu ND, Buckley MG, et al. Atrial natriuretic peptides in essential hypertension: Basal plasma levels and relationship to sodium balance. Can J Physiol Pharmacol 1991, 69:1592-1600.
231. Kohno M, Yasunari K, Murakawa K, et al. Effects of high-sodium and low-sodium intake on circulating atrial natriuretic peptides in salt-sensitive patients with systemic hypertension. Am J Cardiol 1987, 59:1212-1213.
232. Nimura S Attenuated release of atrial natriuretic factor due to sodium loading in salt-sensitive essential hypertension. Jap Heart J 1991, 32:167-178.
233. Campese VM, Tawadrous M, Bigazzi R, et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension 1996, 28:335-340.
234. Ferrari P, Weidmann P, Ferrier C, et al. Dysregulation of atrial natriuretic factor in hypertension-prone man. J Clin Endocrinol Metab 1990, 71:944-951.
235. Weidmann P, Ferrari P, Allemann Y, Ferrier C, Shaw SG Developing essential hypertension: A syndrome involving ANF deficiency?. Can J Physiol Pharmacol 1991, 69:1582-1591.
236. Pitzalis MV, Iacoviello M, Massari F, et al. Influence of gender and family history of hypertension on autonomic control of heart rate, diastolic function and brain natriuretic peptide. J Hypertens 2001, 19:143-148.
237. Rutledge DR, Sun Y, Ross EA Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens 1995, 13:953-955.
238. Beige J, Ringel J, Hohenbleicher H, et al. HpaII-polymorphism of the atrial-natriuretic-peptide gene and essential hypertension in whites. Am J Hypertens 1997, 10:1316-1318.
239. Kato N, Sugiyama T, Morita H, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond) 2000, 98:251-258.
240. Schorr U, Beige J, Ringel J, et al. Hpa II polymorphism of the atrial natriuretic peptide gene and the blood pressure response to salt intake in normotensive men. J Hypertens 1997, 15:715-718.
241. Berge KE, Berg K No effect on blood pressure level or variability of polymorphisms in DNA at the locus for atrial natriuretic factor (ANF). Clin Genet 1994, 46:433-435.
242. Tunny TJ, Jonsson JR, Klemm SA, et al. Association of restriction fragment length polymorphism at the atrial natriuretic peptide gene locus with aldosterone responsiveness to angiotensin in aldosterone-producing adenoma. Biochem Biophys Res Commun 1994, 204:1312-1317.
243. Rahmutula D, Nakayama T, Soma M, et al. Association study between the variants of the human ANP gene and essential hypertension. Hypertens Res 2001, 24:291-294.
244. Maoz E, Shamiss A, Peleg E, et al. The role of atrial natriuretic peptide in natriuresis of fasting. J Hypertens 1992, 10:1041-1044.
245. Maoz E, Shamiss A, Peleg E, et al. The effect of weight reduction on the levels of atrial natriuretic peptide (ANP) in obese hypertensive and normotensive subjects. Metabolism 1991, 40:110-111.
246. Dessi-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997, 15:1695-1699.
247. Dessi-Fulgheri P, Sarzani R, Rappelli A The natriuretic peptide system in obesity-related hypertension: New pathophysiological aspects. J Nephrol 1998, 11:296-299.
248. Sarzani R, Paci VM, Dessi-Fulgheri P, et al. Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues. J Hypertens Suppl 1993, 11:S214-S215.
249. Sarzani R, Dessi-Fulgheri P, Paci VM, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996, 19:581-585.
250. Castro LC, Hobel CJ, Gornbein J Plasma levels of atrial natriuretic peptide in normal and hypertensive pregnancies: A meta-analysis. Am J Obstet Gynecol 1994, 171:1642-1651.
251. Spaanderman M, Ekhart T, van Eyck J, et al. Preeclampsia and maladaptation to pregnancy: A role for atrial natriuretic peptide?. Kidney Int 2001, 60:1397-1406.
252. Minegishi T, Nakamura M, Abe K, et al. Adrenomedullin and atrial natriuretic peptide concentrations in normal pregnancy and pre-eclampsia. Mol Hum Reprod 1999, 5:767-770.
253. Pouta AM, Vuolteenaho OJ, Laatikainen TJ An increase of the plasma N-terminal peptide of proatrial natriuretic peptide in preeclampsia. Obstet Gynecol 1997, 89:747-753.
254. Senoz S, Sahin N, Ozcan T, et al. The concentration of plasma atrial natriuretic peptide in normotensive and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 1995, 62:173-177.
255. Soffronoff EC, Kaufmann BM, Connaughton JF Intravascular volume determinations and fetal outcome in hypertensive diseases of pregnancy. Am J Obstet Gynecol 1977, 127:4-9.
256. Visser W, Wallenburg HC Central hemodynamic observations in untreated preeclamptic patients. Hypertension 1991, 17:1072-1077.
257. Stasch JP, Hirth-Dietrich C, Kazda S, et al. Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo. Life Sci 1989, 45:869-875.
258. Florijn KW, Derkx FH, Visser W, et al. Elevated plasma levels of endothelin in pre-eclampsia. J Hypertens Suppl 1991, 9:S166-S167.
259. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995, 96:1280-1287.
260. Wambach G, Koch J BNP plasma levels during acute volume expansion and chronic sodium loading in normal men. Clin Exp Hypertens 1995, 17:619-629.
261. Tharaux PL, Dussaule JC, Hubert-Brierre J, et al. Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Clin Sci (Lond) 1994, 87:671-677.
262. Grantham JA, Borgeson DD, Burnett JC BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 1997, 272:R1077-R1083.
263. Stevens TL, Rasmussen TE, Wei CM, et al. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Card Fail 1996, 2:119-125.
264. Lisy O, Lainchbury JG, Leskinen H, et al. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, den-droaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001, 37:1089-1094.
265. Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991, 17:1152-1155.
266. Motwani JG, McAlpine H, Kennedy N, et al. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993, 341:1109-1113.
267. Hirata Y, Matsumoto A, Aoyagi T, et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001, 51:585-591.
268. Stevens TL, Burnett JC, Kinoshita M, et al. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995, 95:1101-1108.
269. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide and cGMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998, 101:812-818.
270. Nakamura M, Arakawa N, Yoshida H, et al. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation 1994, 90:1210-1214.
271. Darbar D, Davidson NC, Gillespie N, et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 1996, 78:284-287.
272. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993, 88:82-91.
273. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-ter-minal proatrial natriuretic peptide. Circulation 1996, 93:1963-1969.
274. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-termi-nal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001, 37:1781-1787.
275. Tan AC, van Loenhout TT, Lamfers EJ, et al. Atrial natriuretic peptide after myocardial infarction. Am Heart J 1989, 118:490-494.
276. Kikuta K, Yasue H, Yoshimura M, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996, 132:101-107.
277. Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995, 92:1558-1564.
278. Marumoto K, Hamada M, Hiwada K Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995, 88:551-556.
279. Izumi T, Saito Y, Kishimoto I, et al. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001, 108:203-213.
280. Padilla F, Garcia-Dorado D, Agullo L, et al. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001, 51:592-600.
281. Wozakowska-Kaplon B, Opolski G Atrial natriuretic peptide level after cardioversion of chronic atrial fibrillation. Int J Cardiol 2002, 83:159-165.
282. Rossi A, Enriquez-Sarano M, Burnett JC, et al. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000, 35:1256-1262.
283. Ellenbogen KA, Rogers R, Walsh M, et al. Increased circulating atrial natriuretic factor (ANF) release during induced ventricular tachycardia. Am Heart J 1988, 116:1233-1238.
284. Mookherjee S, Anderson G, Smulyan H, et al. Atrial natriuretic peptide response to cardioversion of atrial flutter and fibrillation and role of associated heart failure. Am J Cardiol 1991, 67:377-380.
285. Petersen P, Kastrup J, Vilhelmsen R, et al. Atrial natriuretic peptide in atrial fibrillation before and after electrical cardioversion therapy. Eur Heart J 1988, 9:639-641.
286. Arakawa M, Miwa H, Kambara K, et al. Changes in plasma concentrations of atrial natriuretic peptides after cardioversion of chronic atrial fibrillation. Am J Cardiol 1992, 70:550-552.
287. Roy D, Paillard F, Cassidy D, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol 1987, 9:509-514. 1987.
288. Inoue S, Murakami Y, Sano K, et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000, 6:92-96.
289. Shimizu H, Murakami O, Inoue S, et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke 2002, 33:1005-1010.
290. Kohno M, Yokokawa K, Yasunari K, et al. Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration. J Cardiovasc Pharmacol 1998, 31:S84-S89.
291. Ikeda M, Kohno M, Yasunari K, et al. Natriuretic peptide family as a novel antimigration factor of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:731-736.
292. Kohno M, Yokokawa K, Yasunari K, et al. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ Res 1997, 81:585-590.
293. Suga S, Nakao K, Mukoyama M, et al. Characterization of natriuretic peptide receptors in cultured cells. Hypertension 1992, 19:762-765.
294. Hirata K, Akita H, Yokoyama M, et al. Impaired vasodilatory response to atrial natriuretic peptide during atherosclerosis progression. Arterioscler Thromb 1992, 12:99-105.
295. Kugiyama K, Sugiyama S, Matsumura T, et al. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Arterioscler Thromb Vasc Biol 1996, 16:1080-1087.
296. Pedersen EB, Danielsen H, Eiskjaer H, et al. Increased atrial natriuretic peptide in the nephrotic syndrome. Relationship to the renal function and the renin-angiotensin-aldosterone system. Scand J Clin Lab Invest 1988, 48:141-147.
297. Rodriguez-Iturbe B, Colic D, Parra G, et al. Atrial natriuretic factor in the acute nephritic and nephrotic syndromes. Kidney Int 1990, 38:512-517.
298. Tulassay T, Rascher W, Lang RE, et al. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome. Kidney Int 1987, 31:1391-1395.
299. Jespersen B, Eiskjaer H, Mogensen CE, et al. Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: A possible role of decreased cyclic guanosine monophosphate. Nephron 1995, 71:44-153.
300. Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999, 230:132-142.
301. Jensen KT, Carstens J, Ivarsen P, et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997, 57:529-540.
302. Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci (Lond) 1992, 83:437-444.
303. Tonolo G, McMillan M, Polonia J, et al. Plasma clearance and effects of alpha-hANP infused in patients with end-stage renal failure. Am J Physiol 1988, 254:F895-F899.
304. Zoccali C, Mallamaci F, Benedetto FA, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001, 12:1508-1515.
305. Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001, 59:1559-1566.
306. Nitta K, Kawashima A, Yumura W, et al. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol 1998, 18:411-415.
307. Holtta T, Happonen JM, Ronnholm K, et al. Hypertension, cardiac state, and the role of volume overload during peritoneal dialysis. Pediatr Nephrol 2001, 16:324-331.
308. Jin H, Yang RH, Chen YF, et al. Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. J Appl Physiol 1991, 71:807-814.
309. Jin H, Yang RH, Chen YF, et al. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest 1990, 85:115-120.
310. Klinger JR, Petit RD, Curtin LA, et al. Cardiopulmonary responses to chronic hypoxia in transgenic mice that overex-press ANP. J Appl Physiol 1993, 75:198-205.
311. Zhao L, Long L, Morrell NW, et al. NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 1999, 99:605-607.
312. Winter RJ, Davidson AC, Treacher D, et al. Atrial natriuretic peptide concentrations in hypoxic secondary pulmonary hypertension: Relation to haemodynamic and blood gas variables and response to supplemental oxygen. Thorax 1989, 44:58-62.
313. Lang CC, Coutie WJ, Struthers AD, et al. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 1992, 83:529-533.
314. Ando T, Ogawa K, Yamaki K, et al. Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Chest 1996, 110:462-468.
315. Tanabe M, Ueda M, Endo M, et al. Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide. Crit Care Med 1994, 22:1762-1768.
316. Mitaka C, Hirata Y, Nagura T, et al. Plasma alpha-human atrial natriuretic peptide concentration in patients with acute lung injury. Am Rev Respir Dis 1992, 146:43-46.
317. Nagaya N, Ando M, Oya H, et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002, 74:180-184; discussion 184.
318. Tulevski II, Hirsch A, Sanson BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001, 86:1193-1196.
319. Rubattu S, Lee-Kirsch MA, DePaolis P, et al. Altered structure, regulation, and function of the gene encoding the atrial natriuretic peptide in the stroke-prone spontaneously hypertensive rat. Circ Res 1999, 85:900-905.
320. Rubattu S, Ridker P, Stampfer MJ, et al. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999, 100:1722-1726.
321. Hassan A, Ali N, Dong Y, et al. Atrial natriuretic peptide gene G664A polymorphism and the risk of ischemic cerebrovascular disease. Neurology 2001, 57:1726-1728.
322. Estrada V, Tellez MJ, Moya J, et al. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke. Am J Hypertens 1994, 7:1085-1089.
323. Yan SD, Fu J, Soto C, et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997, 389:689-695.
324. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998, 273:32730-32738.
325. Valdivieso A The kidney in chronic liver disease: Circulatory abnormalities, renal sodium handling and role of natriuretic peptides. Biol Res 1998, 31:291-304.
326. Bernardi M, Fornale L, Di Marco C, et al. Hyperdynamic circulation of advanced cirrhosis: A re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995, 22:309-318.
327. La Villa G, Romanelli RG, Casini Raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992, 16:156-161.
328. Akriviadis EA, Ervin MG, Cominelli F, et al. Hyponatremia of cirrhosis: Role of vasopressin and decreased 'effective' plasma volume. Scand J Gastroenterol 1997, 32:829-834.
329. Salo J, Jimenez W, Kuhn M, et al. Urinary excretion of urodi-latin in patients with cirrhosis. Hepatology 1996, 24:1428-1432.
330. Wong F, Blendis L Pathophysiology of sodium retention and ascites formation in cirrhosis: Role of atrial natriuretic factor. Semin Liver Dis 1994, 14:59-70.
331. Morali GA, Floras JS, Legault L, et al. Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. Am J Med 1991, 91:383-392.
332. Koepke JP, Jones S, DiBona GF Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol 1987, 252:R1019-R1023.
333. Fabrega E, Crespo J, Rivero M, et al. Dendroaspis natriuretic peptide in hepatic cirrhosis. Am J Gastroenterol 2001, 96:2724-2729.
334. Gulberg V, Moller S, Henriksen JH, et al. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000, 47:852-857.
335. Angeli P, Jimenez W, Arroyo V, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994, 20:948-954.
336. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002, 105:595-601.
337. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001, 111:274-279.
338. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001, 141:367-374.
339. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002, 106:416-422.
340. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
341. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001, 37:379-385.
342. Kruger S, Graf J, Kunz D, et al. brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002, 40:718-722.
343. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350:1349-1353.
344. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998, 351:9-13.
345. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
346. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001, 37:386-391.
347. Kawai K, Hata K, Takaoka H, et al. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: A potential of hormone-guided treatment. Am Heart J 2001, 141:925-932.
348. Vervoort G, Wetzels JF, Lutterman JA, et al. Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. Am J Kidney Dis 2002, 40:9-15.
349. Prasad N, Clarkson PB, MacDonald TM, et al. Atrial natriuretic peptide increases urinary albumin excretion in men with type 1 diabetes mellitus and established microalbuminuria. Diabet Med 1998, 15:678-682.
350. Zietse R, Derkx FH, Weimar W, et al. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. J Am Soc Nephrol 1995, 5:2057-2066.
351. Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993, 341:1105-1109.
352. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999, 20:1799-1807.
353. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997, 96:509-516.
354. Bettencourt P, Ferreira S, Azevedo A, et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 2002, 113:215-219.
355. Jernberg T, Stridsberg M, Lindahl B Usefulness of plasma N-terminal proatrial natriuretic peptide (proANP) as an early predictor of outcome in unstable angina pectoris or non-ST-elevation acute myocardial infarction. Am J Cardiol 2002, 89:64-66.
356. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998, 97:1921-1929.
357. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002, 89:463-465.
358. Hall C, Cannon CP, Forman S, et al. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. J Am Coll Cardiol 1995, 26:1452-1456.
359. Arakawa N, Nakamura M, Aoki H, et al. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996, 27:1656-1661.
360. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998, 135:21-28.
361. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021.
362. Omland T, Aarsland T, Aakvaag A, et al. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 1993, 72:255-259.
363. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994, 24:583-591.
364. Omland T, Bonarjee VV, Nilsen DW, et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: Comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993, 70:409-414.
365. Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994, 89:1934-1942.
366. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999, 34:155-162.
367. Colucci WS Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001, 7:92-100.
368. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000, 343:246-253.
369. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002, 287:1531-1540.
370. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J 2002, 144:1102-1108.
371. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001, 37:1820-1826.
372. Kosuge M, Miyajima E, Kimura K, et al. Comparison of atrial natriuretic peptide versus nitroglycerin for reducing blood pressure in acute myocardial infarction. Am J Cardiol 1998, 81:781-784.
373. Lai CP, Egashira K, Tashiro H, et al. Beneficial effects of atrial natriuretic peptide on exercise-induced myocardial ischemia in patients with stable effort angina pectoris. Circulation 1993, 87:144-151.
374. Tanaka H, Yasue H, Yoshimura M, et al. Suppression of hyper-ventilation-induced attacks with infusion of atrial natriuretic peptide in patients with variant angina pectoris. Am J Cardiol 1993, 72:128-133.
375. Kato H, Yasue H, Yoshimura M, et al. Suppression of hyper-ventilation-induced attacks with infusion of B-type (brain) natriuretic peptide in patients with variant angina. Am Heart J 1994, 128:1098-1104.
376. La Villa G, Lazzeri C, Pascale A, et al. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis. Am J Gastroenterol 1997, 92:852-857.
377. Brenard R, Moreau R, Pussard E, et al. Hemodynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis. J Hepatol 1992, 14:347-356.
378. Gadano A, Moreau R, Vachiery F, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997, 26:1229-1234.
379. Kurnik BR, Weisberg LS, Cuttler IM, et al. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med 1990, 116:27-36.
380. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997, 336:828-834.
381. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000, 36:767-774.
382. Mitaka C, Hirata Y, Nagura T, et al. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 1998, 114:223-228.
383. Bindels AJ, van der Hoeven JG, Groeneveld PH, et al. Atrial natriuretic peptide infusion and nitric oxide inhalation in patients with acute respiratory distress syndrome. Crit Care 2001, 5:151-157.
384. Lin KF, Chao J, Chao L Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension 1999, 33:219-224.
385. Danilewicz JC, Barclay PL, Barnish IT, et al. UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun 1989, 164:58-65.
386. Tikkanen I, Helin K, Tikkanen T, et al. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther 1990, 254:641-645.
387. Northridge DB, Jardine AG, Alabaster CT, et al. Effects of UK 69 578: A novel atriopeptidase inhibitor. Lancet 1989, 2:591-593.
388. Lafferty HM, Gunning M, Silva P, et al. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res 1989, 65:640-646.
389. Maki T, Nasa Y, Yamaguchi F, et al. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res 2001, 51:608-617.
390. Sybertz EJ, Chiu PJ, Vemulapalli S, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 1989, 250:624-631.
391. Gafford JT, Skidgel RA, Erdos EG, et al. Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry 1983, 22:3265-3271.
392. Smits GJ, McGraw DE, Trapani AJ Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: Renal effects. Am J Physiol 1990, 258:F1417-F1424.
393. Northridge DB, Currie PF, Newby DE, et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail 1999, 1:67-72.
394. Northridge DB, Newby DE, Rooney E, et al. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 1999, 138:1149-1157.
395. Newby DE, McDonagh T, Currie PF, et al. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J 1998, 19:1808-1813.
396. Westheim AS, Bostrom P, Christensen CC, et al. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 1999, 34:1794-1801.
397. Matsumura T, Kugiyama K, Sugiyama S, et al. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity. J Clin Invest 1996, 97:2192-2203.
398. Corti R, Burnett JC, Rouleau JL, et al. Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease?. Circulation 2001, 104:1856-1862.
399. Burnett JC Vasopeptidase inhibition. Curr Opin Nephrol Hypertens 2000, 9:465-468.